Related Experiment Video
Updated: Jun 12, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?
Andrea Lancia1, Gianluca Ingrosso2, Beatrice Detti3
1Department of Radiation Oncology, San Matteo Hospital Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pavia, Italy.
Abstract:
The therapeutic landscape of metastatic prostate cancer has undergone a profound revolution in recent years. In addition to the introduction of novel molecules in the clinics, the field has witnessed a tremendous development of functional imaging modalities adding new biological insights which can ultimately inform tailored treatment strategies, including local therapies. The evolution and rise of Stereotactic Body Radiotherapy (SBRT) have been particularly notable in patients with oligometastatic disease, where it has been demonstrated to be a safe and effective treatment strategy yielding favorable results in terms of disease control and improved oncological outcomes. The possibility of debulking all sites of disease, matched with the ambition of potentially extending this treatment paradigm to polymetastatic patients in the not-too-distant future, makes Biology-guided Radiotherapy (BgRT) an attractive paradigm which can be used in conjunction with systemic therapy in the management of patients with metastatic prostate cancer.
Insights
Recent advances in metastatic prostate cancer treatment include novel therapies and functional imaging. Stereotactic Body Radiotherapy (SBRT) shows promise for oligometastatic disease, with Biology-guided Radiotherapy (BgRT) emerging as a future option.
Area of Science:
- Oncology
- Radiotherapy
- Medical Imaging
Background:
- The treatment of metastatic prostate cancer has significantly evolved.
- Novel therapeutic agents and advanced imaging techniques are transforming patient care.
- Functional imaging provides biological insights for personalized treatment strategies.
Purpose of the Study:
- To review the advancements in metastatic prostate cancer therapeutics.
- To highlight the role of Stereotactic Body Radiotherapy (SBRT) in oligometastatic disease.
- To introduce Biology-guided Radiotherapy (BgRT) as a potential future treatment paradigm.
Main Methods:
- Review of recent clinical advancements and research in prostate cancer therapy.
- Analysis of the efficacy and safety of Stereotactic Body Radiotherapy (SBRT).
- Exploration of the potential applications of Biology-guided Radiotherapy (BgRT).
Main Results:
- Stereotactic Body Radiotherapy (SBRT) is a safe and effective treatment for oligometastatic prostate cancer.
- SBRT demonstrates favorable disease control and improved oncological outcomes.
- Biology-guided Radiotherapy (BgRT) offers a promising approach for debulking disease sites.
Conclusions:
- The therapeutic landscape for metastatic prostate cancer is rapidly advancing.
- Stereotactic Body Radiotherapy (SBRT) has proven beneficial for select patients.
- Biology-guided Radiotherapy (BgRT) may expand treatment options, potentially for polymetastatic disease, in combination with systemic therapies.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
05:49Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
Published on: October 10, 2019
